furosemide / Generic mfg. - LARVOL DELTA

A RARE CASE OF STREPTOCOCCUS CRISTATUS ENDOCARDITIS (WRMC 2026) - "The patient had used IV fentanyl and methamphetamine for five years, with most recent use three days prior to presentation...Three blood cultures were obtained prior to initiating IV ceftriaxone and vancomycin...The patient was managed with furosemide and captopril for acute heart failure...This case demonstrates the clinical consequences of Streptococcus cristatusbacteremia, particularly in a patient with poor oral hygiene. Color Doppler Imaging of the Mitral Valve: significant mitral regurgitation (MR) in the setting of extensive vegetations with MR velocity of 4.16 m/s."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Infectious Disease • Inflammation • Pulmonary Disease

MURMUR TO MASS: A DIAGNOSTIC JOURNEY OF A PEDIATRIC CARDIAC TUMOR (WRMC 2026) - "He was discharged on propranolol, aspirin, and furosemide with persistent moderate RVOT obstruction. Lifelong follow-up is essential due to the risks of arrhythmias, progressive obstruction, and recurrence. Large mass seen on echocardiogram: Four chamber view (Left) and Parasternal long view (Right)"

Clinical • Cardiovascular • Fibrosis • Oncology • Pediatrics • Solid Tumor • PTCH1 • SUFU

LOOP DIURETIC–ASSOCIATED BULLOUS PEMPHIGOID (WRMC 2026) - "Prior topical corticosteroids provided no relief, and a short prednisone course improved symptoms but was discontinued due to gastrointestinal and behavioral side effects...Despite high-potency topical steroids, doxycycline, and nicotinamide, his symptoms persisted but improved with continued therapy and later dupilumab...Loop and thiazide diuretics share sulfonamide structures and have been linked to allergic skin reactions, whereas ethacrynic acid and spironolactone do not...This case highlights the diagnostic and therapeutic challenges of BP in an elderly patient with complex comorbidities. Awareness of furosemide as a potential trigger is essential, and careful diuretic selection may mitigate risk. We propose the incorporation of electronic medical record alerts to flag high-risk medications and improve recognition of drug-induced BP."

Alzheimer's Disease • Bullous Pemphigoid • Cardiovascular • CNS Disorders • Congestive Heart Failure • Dementia • Dermatology • Dermatopathology • Diabetes • Eosinophilia • Glaucoma • Heart Failure • Hypertension • Immunology • Metabolic Disorders • Ophthalmology • Type 2 Diabetes Mellitus

Potassium Overdose in Patient with Chronic Kidney Disease on Losartan: A Case Report. (PubMed, Clin Pract Cases Emerg Med) - "This case illustrates how a patient's regularly prescribed medication may complicate the management of an acute overdose. Prompt identification of a patient's medications and supplements may expedite potentially life-saving interventions in a hyperkalemic emergency."

Journal • Cardiovascular • Chronic Kidney Disease • Nephrology • Pain • Renal Disease

Hysteroscopic Morcellation for Management of Early Pregnancy Loss: Evaluation of Clinical Outcomes. (PubMed, J Minim Invasive Gynecol) - "This represents the largest reported cohort to date evaluating hysteroscopic morcellation as the primary treatment for the management of early pregnancy loss. Hysteroscopic morcellation is safe and effective for management of early pregnancy loss with a low rate of complications and intrauterine adhesions post-operatively."

Clinical data • Journal • Gynecology

Malignant Hypertension and Torsades De Pointes as Initial Presentations of Primary Aldosteronism. (PubMed, JACC Case Rep) - "Clinicians must be vigilant about the confounding effects of common antihypertensive agents on ARR interpretation and should consider adrenal imaging as part of the dynamic management of PA. Adrenal venous sampling remains paramount for surgical planning."

Journal • Cardiovascular • Endocrine Disorders • Gynecology • Hypertension • Respiratory Diseases

Granule size-dependent biotransformation of organic micropollutants in aerobic granular sludge under different bioconversion conditions. (PubMed, J Hazard Mater) - "Eight OMPs (sulfamethoxazole, atenolol, furosemide, benzotriazole, trimethoprim, diclofenac, metoprolol, and gabapentin) showed biotransformation efficiencies above 10 % under at least one condition. This study is the first to assess OMP biotransformation across AGS size fractions, highlighting the combined effects of granule size and bioconversion conditions. The findings provide insights for optimizing AGS systems, including potential granule size adjustments, to enhance OMP biotransformation and reduce environmental impacts."

Journal

Using Artificial Intelligence to Assess Treatment-Effect Heterogeneity in Pragmatic Cardiovascular Trials: Insights from TRANSFORM-HF. (PubMed, medRxiv) - "Torsemide appeared more beneficial among patients without atrial fibrillation and with lower BNP/NT-proBNP levels, whereas furosemide was favored in those with atrial fibrillation, higher BNP/NT-proBNP concentrations, and prior loop diuretic use. Exploratory analyses demonstrated that applying AI-driven methods to evaluate treatment effect heterogeneity within a pragmatic trial framework can leverage the inherent clinical diversity of pragmatic designs and potentially generate personalized and practice-relevant insights from pragmatic clinical research."

Heterogeneity • Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Treatment of Refractory Syndrome of Inappropriate Antidiuresis With Sodium-Glucose Cotransporter-2 Inhibitor. (PubMed, AACE Endocrinol Diabetes) - "His serum sodium level remained below 130 mEq/L despite conventional therapy, including fluid restriction, furosemide, and sodium chloride tablets. This case highlights successful normalization of serum sodium levels using empagliflozin monotherapy, suggesting an alternative approach to addressing sodium and water dysregulation in SIAD. Its effectiveness seen in this case of refractory SIAD supports further investigation of empagliflozin in large-scale outpatient setting."

Journal • Cardiovascular • Endocrine Disorders • Head and Neck Cancer • Heart Failure • Laryngeal Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Characteristics of Dexamethasone Palmitate Lipid Nanoparticle in Protecting Against Kanamycin-Induced Ototoxicity: In Vitro and in Vivo Models (ARO 2026) - "For in vivo experiments, adult C57BL/6 mice received subcutaneous kanamycin combined with intraperitoneal furosemide for two consecutive days to induce ototoxicity... DPLN exhibits stable antioxidant effects, mitigating ROS elevation and improving cells survival in vitro. Sustained release of active DEX likely underlies enhanced auditory protection in vivo, resulting in greater and longer-lasting hearing gains compared with DSP. The pronounced suppression of ROS by DPLN indicates its potential as alternative for IT-steroid therapy, effectively overcoming the limited penetration and viability efficacy of conventional DSP in the IE."

Lipid Nanoparticle • Preclinical • Immunology • Inflammation • Osteoarthritis • Otorhinolaryngology • Rheumatoid Arthritis • Rheumatology

Multiomic Analysis Reveals Cell-Type Specific Mechanisms of Cisplatin-Induced Ototoxicity (ARO 2026) - "Our study identified key cochlear genes, pathways, and cell types that are involved in CIO. The SV, OHCs, and T1Ns are confirmed as vulnerable targets, while pOBs emerge as a new contributor. In the SV of cisplatin-treated mice, we observed increased expression of Clu, with inhibition/knockout of this gene reported to enhance the efficacy of cisplatin and reduce kanamycin- and furosemide-induced ototoxicity."

Omic analysis • Metabolic Disorders • Targeted Protein Degradation • COL12A1 • CST3 • TRAP

Characteristics of Dexamethasone Palmitate Lipid Nanoparticle in Protecting Against Kanamycin-Induced Ototoxicity: In Vitro and in Vivo Models (ARO 2026) - "For in vivo experiments, adult C57BL/6 mice received subcutaneous kanamycin combined with intraperitoneal furosemide for two consecutive days to induce ototoxicity... DPLN exhibits stable antioxidant effects, mitigating ROS elevation and improving cells survival in vitro. Sustained release of active DEX likely underlies enhanced auditory protection in vivo, resulting in greater and longer-lasting hearing gains compared with DSP. The pronounced suppression of ROS by DPLN indicates its potential as alternative for IT-steroid therapy, effectively overcoming the limited penetration and viability efficacy of conventional DSP in the IE."

Lipid Nanoparticle • Preclinical • Immunology • Inflammation • Osteoarthritis • Otorhinolaryngology • Rheumatoid Arthritis • Rheumatology

The Potential of Furosemide-Loaded Ovemp as a Diagnostic Test for Endolymphatic Hydrops (ARO 2026) - "The N1–P1 peak-to-peak amplitude of oVEMP was measured before and after furosemide administration, and the improving ratio (IR) was compared between groups. Compared with furosemide-loaded cVEMP, the sensitivity of furosemide-loaded oVEMP was lower. This may be explained by the fact that the prevalence of endolymphatic hydrops in Ménière’s disease is 86% in the saccule, whereas it is 50% in the utricle. Therefore, when using oVEMP, which reflects utricular function, the sensitivity is lower than that obtained with cVEMP, which reflects saccular function."

Otorhinolaryngology

Endocochlear Potential Contributes to Hair Cell Death in TMPRSS3 Hearing Loss (ARO 2026) - "These findings suggest that extracellular factors, including EP, play a role in TMPRSS3-related hair cell survival and hearing loss, and suggest that modulating EP could be a therapeutic strategy."

Otorhinolaryngology • MITF • TMPRSS4

Albumin Based Injectable Gel Enhances Cochlear Delivery Following Intratympanic Injection (ARO 2026) - "Background : Sudden sensorineural hearing loss is often treated with intratympanic (IT) dexamethasone (DEX) injections...Therapeutic efficacy was assessed in kanamycin/furosemide-induced ototoxicity models using auditory brainstem response (ABR), Western blot, and cytokine analysis... The incorporation of albumin-poloxamer drug delivery system into dexamethasone nanosuspension provides enhanced tissue retention, controlled release, and improved biocompatibility. IT administration of NS–albumin–poloxamer gels represents a promising drug delivery strategy for inner ear disorders."

Otorhinolaryngology

Silencing of Ampka Protects Cochlea Hair Cell Against Acute Ototoxicity Damage (ARO 2026) - "Methods : Using a KM-furosemide (KM-FU) acute ototoxicity model in CBA/J mice, we examined the role of AMPKα in cochlear injury... AMPKα activation contributes to KM-FU-induced cochlear damage. Pretreatment with AMPKα siRNA via PSC delivery effectively prevents ototoxic injury, identifying AMPKα as a promising therapeutic target for the prevention of aminoglycoside-induced hearing loss."

Otorhinolaryngology

Furosemide Attenuates Noise-Induced Hearing Loss and Potentiates Preventive Effect of N-Acetylcysteine (ARO 2026) - "Furosemide effectively attenuates NIHL by transiently modulating cochlear physiology and enhancing drug permeability across the BLB. Its combination with NAC offers a promising strategy for preventing NIHL, highlighting a potential therapeutic approach for clinical application."

Otorhinolaryngology

Subtype-Specific Vulnerability of Spiral Ganglion Neurons Across Cochlear Injury Models (ARO 2026) - "Methods : Cochlear injury was induced in adult mice by two approaches: (1) aminoglycoside treatment—gentamicin injection into the posterior semicircular canal or systemic co-administration of kanamycin and furosemide in C57BL/6J mice; and (2) genetic ablation—Pou4f3-DTR/+ mice received intramuscular diphtheria toxin to selectively ablate hair cells. Subtype-specific vulnerability of SGNs is dependent on the nature of cochlear injury. Type Ic SGNs are selectively susceptible to aminoglycoside ototoxicity, whereas genetic hair cell ablation causes uniform degeneration across subtypes. Recognition of SGN subtype diversity is essential for understanding cochlear pathology and for developing targeted neuroprotective strategies."

Infectious Disease • Metabolic Disorders • Otorhinolaryngology • GATA3 • POU4F3

Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy. (PubMed, Am J Cardiovasc Drugs) - P3 | "Patients with ATTR-CM take oral medications administered multiple times a day for the treatment of HF and other comorbidities. As a BID medication, acoramidis does not appear to deviate from non-ATTR-CM pharmacotherapy strategies, and is therefore not expected to impose additional burden in a real-world setting. These data suggest that acoramidis may align with and could possibly be incorporated into patients' existing non-ATTR-CM pharmacotherapeutic regimens."

Journal • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Acute kidney injury requiring temporary hemodialysis due to HELLP syndrome: a case report. (PubMed, CEN Case Rep) - "The patient was treated with intermittent hemodialysis for volume management and renal support, along with a continuous infusion of high-dose furosemide...With appropriate and timely supportive management, renal recovery sufficient for dialysis discontinuation can often be achieved. However, residual impairment may persist, emphasizing the importance of long-term nephrological follow-up after severe HELLP syndrome-associated AKI."

Journal • Acute Kidney Injury • Atypical Hemolytic Uremic Syndrome • Cardiovascular • Chronic Kidney Disease • Complement-mediated Rare Disorders • Hematological Disorders • Hypertension • Nephrology • Renal Disease • Thrombocytopenia • Thrombocytopenic Purpura

Comparison of Effectiveness of Oral Furosemide-Metolazone Versus Oral Furosemide-Spironolactone Combination Therapy in Management of Refractory Edema in Children with Nephrotic Syndrome. (ChiCTR) - P=N/A | N=60 | Not yet recruiting | Sponsor: Khushnood Maqbool; University of Child Health Sciences, The Children's Hospital Lahore.

New trial • Glomerulonephritis • Nephrology • Renal Disease

ProDUCT-HF: Protocol of Diuretics Use in Congestive Therapy in Heart Failure (clinicaltrials.gov) - P4 | N=299 | Completed | Sponsor: University Hospital, Clermont-Ferrand | Recruiting ➔ Completed

Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure

EFFICACY OF HYPERTONIC SALINE SOLUTION IN COMBINATION WITH FUROSEMIDE IN MANAGEMENT OF DECCOMPENSATED HEART FAILURE IN HOSPITALISED PATEINTS : AN UPDATES SYSTEMATIC REVIEW AND META-ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Combination therapy • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Polypharmacy and Drug-Drug Interaction Architecture in Hospitalized Cardiovascular Patients: Insights from Real-World Analysis. (PubMed, Biomedicines) - "Network analysis revealed a limited cluster of hub medications, particularly pantoprazole, furosemide, spironolactone, amiodarone, and perindopril, that disproportionately governed both interaction density and high-severity risk. The study supports the integration of hub-focused deprescribing, targeted monitoring strategies, and network-informed clinical decision support to mitigate DDI risk in cardiovascular polypharmacy. Future studies should link potential DDIs to clinical outcomes and validate network-based prediction models in prospective settings."

Journal • Real-world evidence • Cardiovascular

IMPACT OF ADDING ACETAZOLAMIDE TO FUROSEMIDE IN PATIENTS WITH HEART FAILURE EXACERBATION AND CHRONIC KIDNEY DISEASE: A RETROSPECTIVE MULTICENTER STUDY (ACC 2026) - "Abstract is embargoed at this time."

Retrospective data • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease